Branisteanu D D, Leenaerts P, van Damme B, Bouillon R
Laboratorium Experimentele Geneeskunde en Endocrinologie, University Hospital, Katholieke Universiteit Leuven, Belgium.
Clin Exp Immunol. 1993 Dec;94(3):412-7. doi: 10.1111/j.1365-2249.1993.tb08210.x.
The hormone 1 alpha, 25 dihydroxyvitamin D3 (1,25(OH)2D3) has potent immunosuppressive effects in vitro. Recent publications also described a protective effect of the hormone in various animal models of immune-mediated diseases. To test its in vivo activity we induced active Heymann nephritis in Lewis rats that were either untreated or treated with 1,25(OH)2D3 or its synthetic 20-epi analogue, KH1060. Treatment with cyclosporine A (CsA) was used as an immunosuppressive control. In this nephrotic model the administration of 1,25(OH)2D3 (0.5 microgram/kg body weight) given on alternate days during the first 13 days after active immunization significantly reduced the proteinuria as measured by weeks 7-9. This reduction was comparable to the reduction observed in rats treated with CsA (20 mg/kg) on alternate days. A second series of experiments with 1,25(OH)2D3 confirmed these findings. The level of autoantibodies was found to be significantly suppressed during the treatment time in the CsA (20 mg/kg) group, whereas the limit of significance (P = 0.06) was reached in the 1,25(OH)2D3 (0.5 microgram/kg) group. The size of the immune deposits also was found to be substantially smaller in the groups that developed less proteinuria. The administration of 1,25(OH)2D3 transiently increased the mean serum calcium concentration with 2.5 mg/dl above the pretreatment values, and the urinary calcium excretion by a factor of 3-5 during the short treatment time. Treatment with the analogue KH1060 did not reduce the proteinuria significantly. Our experiments add evidence to the hypothesis that 1,25(OH)2D3 in pharmacological doses has immunosuppressive potency.
激素1α,25-二羟基维生素D3(1,25(OH)2D3)在体外具有强大的免疫抑制作用。近期发表的文献也描述了该激素在各种免疫介导疾病的动物模型中的保护作用。为测试其体内活性,我们在Lewis大鼠中诱导了活动性海曼肾炎,这些大鼠未接受治疗或接受1,25(OH)2D3或其合成的20-表位类似物KH1060治疗。环孢素A(CsA)治疗用作免疫抑制对照。在这个肾病模型中,在主动免疫后的前13天隔日给予1,25(OH)2D3(0.5微克/千克体重),显著降低了第7 - 9周测量的蛋白尿。这种降低与隔日接受CsA(20毫克/千克)治疗的大鼠中观察到的降低相当。另一系列用1,25(OH)2D3进行的实验证实了这些发现。发现CsA(20毫克/千克)组在治疗期间自身抗体水平显著受到抑制,而1,25(OH)2D3(0.5微克/千克)组达到显著水平极限(P = 0.06)。在蛋白尿较少的组中还发现免疫沉积物的大小明显更小。给予1,25(OH)2D3使平均血清钙浓度短暂升高,比预处理值高2.5毫克/分升,并且在短治疗时间内尿钙排泄增加3 - 5倍。用类似物KH1060治疗未显著降低蛋白尿。我们的实验为药理学剂量的1,25(OH)2D3具有免疫抑制效力这一假说增添了证据。